SEC Filing Summary: Pieris Pharmaceuticals, Inc. (PIRS)
Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on May 9, 2024, reporting an event that occurred on May 7, 2024. The registrant is a Nevada corporation with principal executive offices in Boston, MA, and its common stock trades on The Nasdaq Capital Market under the symbol "PIRS".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The primary material event reported is the resolution of a listing deficiency. The Company received notification from The Nasdaq Stock Market confirming that the closing bid price of its common stock remained at or above $1.00 per share for 10 consecutive business days (April 23 to May 6, 2024). Consequently, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of future risks and contingencies beyond the resolution of the specific listing compliance issue.
Investor Verification Checklist
- Verify the current trading price of PIRS to ensure continued compliance with Nasdaq minimum bid price requirements.
- Confirm the status of the Company's compliance with other Nasdaq listing rules, as this filing addresses only Rule 5550(a)(2).
- Review recent 10-Q or 10-K filings for the most up-to-date financial position, as this 8-K contains no financial data.